Drug intelligence / Profile preview

Tagmokitug

Development stage: Preclinical
Lead developer: Coherus BioSciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Tagmokitug is an anti-CCR8 antibody developed for immuno-oncology. It is currently in preclinical to early-clinical stages and is intended for combination therapies with LOQTORZI in various solid tumors. The drug was originally developed by Surface Oncology, which was acquired by Coherus Oncology in August 2022.

Targets

CCR8

Beyond the preview

Go deeper on Tagmokitug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tagmokitug.

Explore the full profile